drugset
drugset / Trial / NCT03131206

A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer

NCT03131206 ↗

Phase 1/2 Terminated 5 enrolled Dana-Farber Cancer Institute Genentech, Inc. · collab
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This research trial is studying a drug called alectinib as a possible treatment for non-small cell lung cancer (NSCLC) with specific genetic alterations known as ALK or RET rearrangements, and thyroid cancer with RET rearrangements.

Timeline

Start
2017-06-19
Primary completion
2018-11-08
Completion
2019-04-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Alectinib Small molecule — Oral

Indications

malignant endocrine neoplasm non-small cell lung carcinoma